دورية أكاديمية
أعرض في EDS

Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes.

التفاصيل البيبلوغرافية
العنوان: Dual role of GRHL3 in bladder carcinogenesis depending on histological subtypes.
المؤلفون: Lammert FC; Institute of Pathology, University Hospital, RWTH Aachen University, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany., Pannhausen J; Institute of Pathology, University Hospital, RWTH Aachen University, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany., Noetzel E; Institute of Biological Information Processing 2 (IBI-2), Mechanobiology, Forschungszentrum Jülich GmbH, Germany., Friedland F; Institute of Biological Information Processing 2 (IBI-2), Mechanobiology, Forschungszentrum Jülich GmbH, Germany., Wirtz J; Institute of Pathology, University Hospital, RWTH Aachen University, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany., Herfs Y; Institute of Biological Information Processing 2 (IBI-2), Mechanobiology, Forschungszentrum Jülich GmbH, Germany., Leypold S; Institute of Pathology, University Hospital, RWTH Aachen University, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany., Gan L; IZKF Aachen, Medical Faculty of the RWTH Aachen University, Germany., Weiskirchen R; Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC), University Hospital, RWTH Aachen University, Germany., Schnitzler T; Institute of Pathology, University Hospital, RWTH Aachen University, Germany., Knüchel R; Institute of Pathology, University Hospital, RWTH Aachen University, Germany., Maurer J; Department of Obstetrics and Gynecology, University Hospital Aachen, Germany., Jonigk DD; Institute of Pathology, University Hospital, RWTH Aachen University, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.; German Center for Lung Research, DZL, BREATH, Hanover, Germany., Rose M; Institute of Pathology, University Hospital, RWTH Aachen University, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.; Institute of Pathology, University Hospital, University of Ulm, Germany., Gaisa NT; Institute of Pathology, University Hospital, RWTH Aachen University, Germany.; Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD), Germany.; Institute of Pathology, University Hospital, University of Ulm, Germany.
المصدر: Molecular oncology [Mol Oncol] 2024 Jun; Vol. 18 (6), pp. 1397-1416. Date of Electronic Publication: 2024 Mar 02.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: John Wiley & Sons, Inc Country of Publication: United States NLM ID: 101308230 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1878-0261 (Electronic) Linking ISSN: 15747891 NLM ISO Abbreviation: Mol Oncol Subsets: MEDLINE
أسماء مطبوعة: Publication: 2017- : Hoboken, New Jersey : John Wiley & Sons, Inc.
Original Publication: Amsterdam : Elsevier
مواضيع طبية MeSH: Urinary Bladder Neoplasms*/genetics , Urinary Bladder Neoplasms*/pathology , Urinary Bladder Neoplasms*/metabolism , Transcription Factors*/metabolism , Transcription Factors*/genetics , DNA-Binding Proteins*/genetics , DNA-Binding Proteins*/metabolism , Gene Expression Regulation, Neoplastic* , Carcinogenesis*/genetics , Carcinogenesis*/pathology, Humans ; Cell Line, Tumor ; Female ; Male ; rhoA GTP-Binding Protein/metabolism ; rhoA GTP-Binding Protein/genetics ; Cell Movement/genetics ; Cell Proliferation/genetics ; Carcinoma, Squamous Cell/genetics ; Carcinoma, Squamous Cell/pathology ; Carcinoma, Squamous Cell/metabolism ; Prognosis ; Eukaryotic Initiation Factor-4E/metabolism ; Eukaryotic Initiation Factor-4E/genetics ; Aged
مستخلص: The effect of grainyhead-like transcription factor 3 (GRHL3) on cancer development depends on the cancer subtypes as shown in tumor entities such as colorectal or oral squamous cell carcinomas. Here, we analyzed the subtype-specific role of GRHL3 in bladder carcinogenesis, comparing common urothelial carcinoma (UC) with squamous bladder cancer (sq-BLCA). We examined GRHL3 mRNA and protein expression in cohorts of patient samples, its prognostic role and its functional impact on tumorigeneses in different molecular and histopathological subtypes of bladder cancer. We showed for GRHL3 a reverse expression in squamous and urothelial bladder cancer subtypes. Stably GRHL3-overexpressing EJ28, J82, and SCaBER in vitro models revealed a tumor-suppressive function in squamous and an oncogenic role in the urothelial cancer cells affecting cell and colony growth, and migratory and invasive capacities. Transcriptomic profiling demonstrated highly subtype-specific GRHL3-regulated expression networks coined by the enrichment of genes involved in integrin-mediated pathways. In SCaBER, loss of ras homolog family member A (RHOA) GTPase activity was demonstrated to be associated with co-regulation of eukaryotic translation initiation factor 4E family member 3 (EIF4E3), a potential tumor suppressor gene. Thus, our data provide for the first time a detailed insight into the role of the transcription factor GRHL3 in different histopathological subtypes of bladder cancer.
(© 2024 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
References: Wilehm Roux Arch Dev Biol. 1984 Sep;193(5):267-282. (PMID: 28305337)
Tumour Biol. 2014 Mar;35(3):1827-31. (PMID: 24363083)
Acta Biochim Biophys Sin (Shanghai). 2016 Mar;48(3):266-74. (PMID: 26837418)
Cancer Cell. 2011 Nov 15;20(5):635-48. (PMID: 22094257)
Pathologe. 1987 May;8(3):138-40. (PMID: 3303008)
Nucleic Acids Res. 2013 Apr;41(8):4378-91. (PMID: 23444143)
Exp Biol Med (Maywood). 2015 Nov;240(11):1396-401. (PMID: 26069269)
Mol Cancer. 2017 Feb 23;16(1):44. (PMID: 28231808)
Cell Oncol (Dordr). 2020 Oct;43(5):807-819. (PMID: 32445084)
Bioinformatics. 2014 Apr 1;30(7):923-30. (PMID: 24227677)
Front Mol Biosci. 2020 Aug 21;7:213. (PMID: 32974388)
Exp Biol Med (Maywood). 2020 Mar;245(5):402-410. (PMID: 32008358)
Cancer Manag Res. 2020 Jun 02;12:4085-4096. (PMID: 32581582)
Carcinogenesis. 2016 May;37(5):500-10. (PMID: 26933170)
Small GTPases. 2010 Sep;1(2):104-107. (PMID: 21686262)
Tumour Biol. 2016 Jul;37(7):9657-61. (PMID: 26797800)
Genome Biol. 2014;15(12):550. (PMID: 25516281)
Urol Oncol. 2019 Jun;37(6):353.e17-353.e24. (PMID: 30704959)
Mol Carcinog. 2018 Feb;57(2):167-181. (PMID: 28940371)
BMC Cancer. 2018 Jan 4;18(1):23. (PMID: 29301499)
Dev Biol. 2011 Jan 15;349(2):512-22. (PMID: 21081122)
Eur Urol. 2020 Apr;77(4):420-433. (PMID: 31563503)
Cell Adh Migr. 2013 May-Jun;7(3):293-6. (PMID: 23628962)
Nat Biotechnol. 2020 Mar;38(3):276-278. (PMID: 32055031)
Int J Mol Sci. 2021 Mar 15;22(6):. (PMID: 33803949)
Oncotarget. 2017 May 16;8(20):33694-33703. (PMID: 28402270)
Curr Opin Cell Biol. 2011 Oct;23(5):569-78. (PMID: 21807492)
Am J Transl Res. 2017 Sep 15;9(9):4217-4226. (PMID: 28979695)
PLoS Genet. 2017 Apr 26;13(4):e1006745. (PMID: 28445475)
Oncogene. 2017 Nov 2;36(44):6067-6073. (PMID: 28714958)
Biomedicines. 2022 May 30;10(6):. (PMID: 35740300)
Virchows Arch. 2021 Aug;479(2):325-335. (PMID: 33650041)
Cancer Control. 2018 Jan-Dec;25(1):1073274818800269. (PMID: 30213195)
Nature. 2014 Mar 20;507(7492):315-22. (PMID: 24476821)
Cancer Discov. 2012 May;2(5):401-4. (PMID: 22588877)
Biochem J. 2003 Mar 15;370(Pt 3):953-62. (PMID: 12549979)
PLoS One. 2013;8(2):e56116. (PMID: 23437087)
Onco Targets Ther. 2020 Apr 17;13:3237-3245. (PMID: 32368082)
Proc Natl Acad Sci U S A. 2013 Mar 5;110(10):3877-82. (PMID: 23431134)
Curr Biol. 2003 Jul 1;13(13):1106-15. (PMID: 12842009)
Biol Open. 2013 Mar 15;2(3):351-61. (PMID: 23519595)
Cell. 2017 Oct 19;171(3):540-556.e25. (PMID: 28988769)
CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108. (PMID: 15761078)
BJU Int. 2013 Nov;112 Suppl 2:27-31. (PMID: 24127673)
EMBO J. 2009 Jul 8;28(13):1890-903. (PMID: 19494835)
Nucleic Acids Res. 2021 Jan 8;49(D1):D605-D612. (PMID: 33237311)
Bioinformatics. 2013 Jan 1;29(1):15-21. (PMID: 23104886)
Virchows Arch. 2011 Mar;458(3):301-12. (PMID: 21136076)
Dev Cell. 2010 Jul 20;19(1):138-47. (PMID: 20643356)
J Biol Chem. 2009 Dec 18;284(51):35287-96. (PMID: 19850923)
Med Sci Monit. 2020 Jan 02;26:e920670. (PMID: 31929497)
Essays Biochem. 2019 Oct 31;63(5):483-495. (PMID: 31551324)
Sci Signal. 2013 Apr 02;6(269):pl1. (PMID: 23550210)
J Natl Cancer Inst. 2015 Jun 10;107(9):. (PMID: 26063791)
Science. 2005 Apr 15;308(5720):411-3. (PMID: 15831758)
Oncogene. 2013 Mar 21;32(12):1497-507. (PMID: 22614019)
Nat Methods. 2017 Apr;14(4):417-419. (PMID: 28263959)
Urology. 2009 Apr;73(4):822-7. (PMID: 19193403)
Oncotarget. 2020 Jul 07;11(27):2611-2624. (PMID: 32676163)
Small GTPases. 2014;5:e28997. (PMID: 25054920)
Int Urol Nephrol. 2007;39(3):803-7. (PMID: 17333523)
Eur Urol. 2016 Jul;70(1):106-119. (PMID: 26996659)
BMC Cancer. 2023 Feb 1;23(1):113. (PMID: 36726072)
J Huazhong Univ Sci Technolog Med Sci. 2017 Dec;37(6):880-885. (PMID: 29270747)
معلومات مُعتمدة: 62/22 START Program of the Medical Faculty of the RWTH Aachen University
فهرسة مساهمة: Keywords: GRHL3; RHO GTPase; bladder cancer; oncogene; squamous cell carcinoma; tumor suppressor gene
المشرفين على المادة: 0 (GRHL3 protein, human)
0 (Transcription Factors)
0 (DNA-Binding Proteins)
EC 3.6.5.2 (rhoA GTP-Binding Protein)
0 (Eukaryotic Initiation Factor-4E)
تواريخ الأحداث: Date Created: 20240302 Date Completed: 20240608 Latest Revision: 20240618
رمز التحديث: 20240618
مُعرف محوري في PubMed: PMC11164254
DOI: 10.1002/1878-0261.13623
PMID: 38429970
قاعدة البيانات: MEDLINE
الوصف
تدمد:1878-0261
DOI:10.1002/1878-0261.13623